The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CCI, ALGN and ANAB

NEW YORK, NY / ACCESSWIRE / March 30, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Crown Castle International Corp. (NYSE:CCI)
Class Period: February 26, 2018 to February 26, 2020
Lead Plaintiff Deadline: April 27, 2020

The CCI lawsuit alleges Crown Castle International Corp. made materially false and/or misleading statements and/or failed to disclose during the class period that: 1) Crown Castle's internal control over financial reporting and disclosures controls and procedures were ineffective and materially weak; (2) Crown Castle's financial accounting and reporting was not in accordance with GAAP; (3) Crown Castle's net income, adjusted EBITDA, and AFFO were inflated; (4) Crown Castle would need to restate its financial statements for the years ended December 31, 2018 and 2017, and unaudited financial information for the quarterly and year-to-date periods in the year ended December 31, 2018 and for the first three quarters in the year ended December 31, 2019; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in CCI: http://www.kleinstocklaw.com/pslra-1/crown-castle-international-corp-loss-submission-form?id=5858&from=1

Align Technology, Inc. (NASDAQ:ALGN)
Class Period: April 24, 2019 to July 24, 2019
Lead Plaintiff Deadline: May 1, 2020

According to the complaint, Align Technology, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) Align was then experiencing a significant decline in demand for its products in the important Chinese market; (b) Chinese consumer sentiment towards the Company was deteriorating; and (c) as a result of the foregoing, Defendants' positive statements about Align and its businesses were lacking in a reasonable basis.

Learn about your recoverable losses in ALGN: http://www.kleinstocklaw.com/pslra-1/align-technology-inc-loss-submission-form-2?id=5858&from=1

AnaptysBio, Inc. (NASDAQ:ANAB)
Class Period: October 10, 2017 to November 7, 2019
Lead Plaintiff Deadline: May 26, 2020

The complaint alleges that during the class period AnaptysBio, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in ANAB: http://www.kleinstocklaw.com/pslra-1/anaptysbio-inc-loss-submission-form?id=5858&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 583241